Wall Street analysts expect Teva Pharmaceutical Industries Ltd (NYSE:TEVA) to post $4.30 billion in sales for the current fiscal quarter, according to Zacks. Seven analysts have provided estimates for Teva Pharmaceutical Industries’ earnings, with the highest sales estimate coming in at $4.38 billion and the lowest estimate coming in at $4.18 billion. Teva Pharmaceutical Industries posted sales of $4.56 billion in the same quarter last year, which suggests a negative year-over-year growth rate of 5.7%. The firm is expected to announce its next earnings report on Wednesday, February 12th.
On average, analysts expect that Teva Pharmaceutical Industries will report full year sales of $17.24 billion for the current year, with estimates ranging from $17.13 billion to $17.36 billion. For the next financial year, analysts expect that the company will report sales of $17.07 billion, with estimates ranging from $16.63 billion to $17.76 billion. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Teva Pharmaceutical Industries.
Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, August 7th. The company reported $0.57 EPS for the quarter, beating the consensus estimate of $0.55 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 16.04% and a negative net margin of 21.94%. The company had revenue of $4.34 billion for the quarter, compared to analysts’ expectations of $4.25 billion. During the same period last year, the firm posted $0.78 earnings per share. Teva Pharmaceutical Industries’s revenue was down 7.7% compared to the same quarter last year.
Several equities research analysts recently commented on TEVA shares. Gabelli raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Wednesday, October 16th. BMO Capital Markets dropped their price objective on Teva Pharmaceutical Industries from $11.00 to $9.00 and set a “market perform” rating on the stock in a research report on Friday, August 9th. Guggenheim started coverage on Teva Pharmaceutical Industries in a research report on Thursday, September 12th. They set a “neutral” rating on the stock. SunTrust Banks dropped their price objective on Teva Pharmaceutical Industries to $7.00 and set a “hold” rating on the stock in a research report on Thursday, August 8th. Finally, Morgan Stanley cut Teva Pharmaceutical Industries from an “equal weight” rating to an “underweight” rating and dropped their price objective for the company from $16.00 to $6.00 in a research report on Monday, July 15th. Six analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $10.78.
A number of hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC raised its stake in shares of Teva Pharmaceutical Industries by 272.6% in the second quarter. Renaissance Technologies LLC now owns 9,786,063 shares of the company’s stock worth $90,325,000 after buying an additional 7,159,900 shares during the period. Price T Rowe Associates Inc. MD raised its stake in shares of Teva Pharmaceutical Industries by 20.0% in the second quarter. Price T Rowe Associates Inc. MD now owns 9,553,328 shares of the company’s stock worth $88,177,000 after buying an additional 1,593,139 shares during the period. Commerzbank Aktiengesellschaft FI raised its stake in shares of Teva Pharmaceutical Industries by 49.4% in the third quarter. Commerzbank Aktiengesellschaft FI now owns 8,682,389 shares of the company’s stock worth $59,735,000 after buying an additional 2,869,139 shares during the period. Northern Trust Corp raised its stake in shares of Teva Pharmaceutical Industries by 12.5% in the second quarter. Northern Trust Corp now owns 7,610,010 shares of the company’s stock worth $70,239,000 after buying an additional 846,650 shares during the period. Finally, Camber Capital Management LP raised its stake in shares of Teva Pharmaceutical Industries by 85.7% in the second quarter. Camber Capital Management LP now owns 6,500,000 shares of the company’s stock worth $59,995,000 after buying an additional 3,000,000 shares during the period. 58.21% of the stock is currently owned by institutional investors.
Shares of Teva Pharmaceutical Industries stock traded up $0.83 during trading on Thursday, hitting $9.30. 34,192,717 shares of the company’s stock traded hands, compared to its average volume of 16,922,125. The company has a debt-to-equity ratio of 1.73, a current ratio of 0.96 and a quick ratio of 0.62. Teva Pharmaceutical Industries has a 1 year low of $6.07 and a 1 year high of $23.97. The stock has a market capitalization of $9.32 billion, a P/E ratio of 3.32, a PEG ratio of 0.89 and a beta of 1.73. The business has a 50-day simple moving average of $7.51 and a 200-day simple moving average of $8.90.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Featured Article: Google Finance Portfolio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.